Aspirin prevented cancer metastasis

Scientists analyzed all available data on the use of aspirin in cancer patients. It turned out that taking the drug in low doses prevented cancer metastasis, reduced the risk of cardiovascular complications, mortality from cancer and overall mortality.

Researchers from Cardiff University in the UK analyzed the benefits and risks of taking low-dose aspirin for cancer. The results of the study were published in the British Journal of Cancer.

They analyzed data from about 1 million patients who participated in 118 studies to assess mortality in cancer patients.

The authors found a decrease in the incidence of metastatic cancer and vascular complications in cancer patients against the background of aspirin intake. The analysis showed that aspirin in low doses (75-81 mg/day) reduced all-cause mortality by 20%. According to some studies, the drug also reduced mortality from cancer. In addition, taking aspirin has been shown to reduce the risk of cancer metastasis by 38-52%. The drug also protected against thrombosis, including venous thrombosis, the risk of which increases with cancer.

Evidence against aspirin use included an increased risk of gastrointestinal bleeding. However, there was no reliable evidence of an association between taking the drug and fatal gastrointestinal bleeding.

Thus, given the relative safety and beneficial effects of aspirin, the authors consider the use of this drug in cancer to be justified. The earlier one starts taking the drug after the diagnosis of cancer, the more benefits can be expected from aspirin.